Drug Profile


Alternative Names: '444; 642444; GSK-642444; GW 642444; GW642444H; GW642444M; GW642444X; Vilanterol trifenatate

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline; Theravance
  • Developer GlaxoSmithKline; Innoviva; Theravance
  • Class Antiasthmatics; Chlorobenzenes; Ethers; Phenols; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic obstructive pulmonary disease
  • Phase II Asthma

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 21 Nov 2016 Innoviva is eligible to receive associated royalty revenues from GSK if Vilanterol is approved and commercialised
  • 01 Sep 2015 No recent reports on development identified - Phase-I for Chronic obstructive pulmonary disease (In volunteers) in China (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top